Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Prior treatment

• Prior locoregional therapy (such as TACE、TAE、HAIC、TARE)
• Prior allogeneic stem cell or solid organ transplantation

Other illness

• Other active malignant tumor except HCC within 5 years or simultaneously
• History of hepatic encephalopathy

Other

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
• There is an absolute contraindication to HAIC
• Diffuse HCC, intrahepatic tumor burden \> 50%
• PVTT reaching the superior mesenteric vein, and bilateral PVTT are present
• Clinically significant ascites

• Signed Informed Consent Form (ICF)
• Aged ≥18 years and ≤75 years at time of signing ICF
• Documented diagnosis of HCC confirmed by histology/cytology or clinically
• Patients with BCLC stage B (the sum of number of tumors and the maximum diameter of the largest tumor exceeding Up-to-7 criteria) and BCLC stage C without extrahepatic metastasis: ① tumors confined to one lobe (left, right, or middle lobe), or tumors in one lobe are present alongside a single tumor with diameter ≤5 cm or up to three tumors each with diameter ≤3 cm in the remaining lobes; ②No PVTT involving the contralateral liver lobe or reaching the superior mesenteric vein. And no tumor thrombus of the inferior vena cava reaching right atrium
• Patients with recurrence following prior radical surgical resection must have undergone the initial surgery at least 5 years prior to study entry
• At least one measurable lesion (per RECIST v1.1) untreated lesion
• ECOG performance status of 0 or 1
• Child-Pugh ≤7 score
• Life expectancy ≥12 weeks
• Adequate organ function
• No prior anti-tumor systemic therapies for HCC